Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis

Biochemical and Biophysical Research Communications

Volumn 356, Issue 1, 2007, Pages 53-59

  Yu, Jun ^a   Chu, Eagle S H ^a   Hui, Alex Y ^a   Cheung, Kin F ^a   Chan, Henry L Y ^a   Leung, Wai K ^a   Farrell, Geoffrey C ^b   Sung, Joseph J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Cytokines; Lipoprotein lipase; NO 1886; Nutritional steatohepatitis; Peroxisome proliferator activated receptor

Indexed keywords

4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID DIETHYL ESTER; ACYL COENZYME A OXIDASE; CHOLINE; CYCLOOXYGENASE 2; CYTOCHROME P450 4A; CYTOCHROME P450 4A10; FATTY ACID; INTERLEUKIN 6; LIPID PEROXIDE; LIPOPROTEIN LIPASE; METHIONINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FATTY LIVER; GENE CONTROL; INFLAMMATION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTILIPEMIC AGENTS; BENZAMIDES; CHOLESTEROL; CHOLINE DEFICIENCY; CYCLOOXYGENASE 2; DIET; ENZYME ACTIVATION; FATTY LIVER; GENE EXPRESSION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LIPOGENESIS; LIPOPROTEIN LIPASE; LIPOPROTEINS, HDL; LIVER; MALE; METHIONINE; MICE; MICE, INBRED C57BL; ORGANOPHOSPHORUS COMPOUNDS; PPAR GAMMA; RNA, MESSENGER; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 33947172627     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.02.129     Document Type: Article

References (35)

1. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., and Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005) 1343-1351
2. Farrell G.C. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. J. Gastroenterol. Hepatol. 18 (2003) 124-138
3. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006) S99-S112
4. Ip E., Farrell G.C., Robertson G., Hall P., Kirsch R., and Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38 (2003) 123-132
5. Ip E., Farrell G., Hall P., Robertson G., and Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39 (2004) 1286-1296
6. Yu J., Ip E., Dela Pena A., Hou J.Y., Sesha J., Pera N., Hall P., Kirsch R., Leclercq I., and Farrell G.C. COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatology 43 (2006) 826-836
7. Tsutsumi K., Inoue Y., Shima A., and Murase T. Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes 44 (1995) 414-417
8. Yin W., Yuan Z., Tsutsumi K., Xie Y., Zhang Q., Wang Z., Fu G., Long G., and Ang Y. A lipoprotein lipase-promoting agent, NO-1886, improves glucose and lipid metabolism in high fat, high sucrose-fed New Zealand White rabbits. Int. J. Exp. Diabesity Res. 4 (2003) 27-34
9. Kusunoki M., Hara T., Tsutsumi K., Nakamura T., Miyata T., Sakakibara F., Sakamoto S., Ogawa H., Nakaya Y., and Storlien L.H. The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet. Diabetologia 43 (2000) 875-880
10. Tsutsumi K., Inoue Y., Shima A., Iwasaki K., Kawamura M., and Murase T. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J. Clin. Invest. 92 (1993) 411-417
11. Leclercq I.A., Farrell G.C., Field J., Bell D.R., Gonzalez F.J., and Robertson G.R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 105 (2000) 1067-1075
12. Koppe S.W., Sahai A., Malladi P., Whitington P.F., and Green R.M. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J. Hepatol. 41 (2004) 592-598
13. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114 (2004) 147-152
14. Lowell B.B., and Shulman G.I. Mitochondrial dysfunction and type 2 diabetes. Science 307 (2005) 384-387
15. Anania F.A. Adiponectin and alcoholic fatty liver: is it, after all, about what you eat?. Hepatology 42 (2005) 530-532
16. Donnelly K.L., Smith C.L., Schwarzenberg S.J., Jessurun J., Boldt B.D., and Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005) 1343-1351
17. Tamura S., and Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005) 1139-1142
18. Hagi A., Hirai I., Kohri H., and Tsutsumi K. The novel compound NO-1886 activates lipoprotein lipase in primary cultured adipose and skeletal muscle cells. Biol. Pharm. Bull. 20 (1997) 1108-1110
19. Marchesini G., Bugianesi E., Forlani G., Marzocchi R., Zannoni C., Vanni E., Manini R., Rizzetto M., and Melchionda N. Non-alcoholic steatohepatitis in patients cared in metabolic units. Non-alcoholic steatohepatitis in patients cared in metabolic units. Diabetes Res. Clin. Pract. 63 (2004) 143-151
20. Koruk M., Savas M.C., Yilmaz O., Taysi S., Karakok M., Gundogdu C., and Yilmaz A. Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 37 (2003) 177-182
21. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., Natale S., Vanni E., Villanova N., Melchionda N., and Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
22. Setji T.L., Holland N.D., Sanders L.L., Pereira K.C., Mae Diehl A., and Brown A.J. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91 (2006) 1741-1747
23. Dela Pena A., Leclercq I., Field J., George J., Jones B., and Farrell G. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 129 (2005) 1663-1674
24. Leclercq I.A., Farrell G.C., Sempoux C., Dela Pena A., and Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J. Hepatol. 41 (2004) 926-934
25. Kiemer A.K., Hartung T., Huber C., and Vollmar A.M. Phyllanthus amarus has anti-inflammatory potential by inhibition of iNOS, COX-2, and cytokines via the NF-kappaB pathway. J. Hepatol. 38 (2003) 289-297
26. Lieber C.S. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J. Hepatol. 32 (2000) 113-128
27. Teoh N.C., and Farrell G.C. Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. J. Gastroenterol. Hepatol. 18 (2003) 891-902
28. Yin W., Liao D., Wang Z., Xi S., Tsutsumi K., Koike T., Fan J., Yi G., Zhang Q., Yuan Z., and Tang K. NO-1886 inhibits size of adipocytes, suppresses plasma levels of tumor necrosis factor-alpha and free fatty acids, improves glucose metabolism in high-fat/high-sucrose-fed miniature pigs. Pharmacol. Res. 49 (2004) 199-206
29. Niho N., Mutoh M., Takahashi M., Tsutsumi K., Sugimura T., and Wakabayashi K. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc. Natl. Acad. Sci. USA 102 (2005) 2970-2974
30. Shimano H., Horton J.D., Hammer R.E., Shimomura I., Brown M.S., and Goldstein J.L. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Invest. 98 (1996) 1575-1584
31. Shimano H., Horton J.D., Shimomura I., Hammer R.E., Brown M.S., and Goldstein J.L. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J. Clin. Invest. 99 (1997) 846-854
32. Shimomura I., Shimano H., Korn B.S., Bashmakov Y., and Horton J.D. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J. Biol. Chem. 273 (1998) 35299-35306
33. Rao M.S., and Reddy J.K. PPARalpha in the pathogenesis of fatty liver disease. Hepatology 40 (2004) 783-786
34. Reddy J.K., and Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 21 (2001) 193-230
35. Wan Y.J., Cai Y., Li J., Yuan Q.X., French B., Gonzalez F.J., and French S. Regulation of peroxisome proliferator activated receptor α-mediated pathways in alcohol fed cytochrome P450 2E1 deficient mice. Hepatol. Res. 19 (2001) 117-130